New research in breast cancer is ongoing all around the world …
New research in breast cancer is ongoing all around the world …
As part of Breast Cancer Awareness month Purdue University is …
Updated: Tuesday, 15 Jan 2013, 4:26 PM EST
Published : Tuesday, 15 Jan 2013, 4:25 PM EST
LONDON (AP) - Britain's National Health Service may soon offer women at high risk of developing breast cancer drugs normally used to treat the disease as a prevention strategy.
The National Institute for Health and Clinical Excellence on Tuesday announced draft guidelines that would make the drugs available.
A final decision is expected this spring after medical groups, charities and patients' organization respond to the proposal.
The proposal suggests that tamoxifen or raloxifene should be used by women found at high risk of developing the disease.
Clinical trials have shown the drugs can be effective in cutting breast cancer rates, and the medications are used both to treat and to prevent the disease in other countries, including the United States.
Initial response from charities and patients groups to the proposal has been favorable.
The charity Breakthrough Breast Cancer called the move "an historic step" in the fight against the deadly disease.
Specialist nurse Jackie Harris with the Breast Cancer Care charity said the proposal could be "very good news" for women with a family history of breast cancer, but doctors cautioned that the drugs cannot be viewed as a vaccine against breast cancer.
Comments WLFI.com is migrating to a more stable commenting system called DISQUS. This system is used by CNN, TIME, FOX News, numerous blogging sites and has over 75 Million registered users. Unfortunately we can't migrate our current user accounts to this new system.
To sign up for a DISQUS account, click the DISQUS button just below and to the right and then click Login.
DISQUS lets you login with several different options, including Facebook, Google, Twitter, Yahoo or OpenID. We expect it to allow more conversation and better moderation. If you have any questions, please feel free to comment below.